Osteopontin as a marker in thyroid disease: Relation to body mass index

El‐Zawawy, Hanaa Tarek; El-Aghoury, Aliaa Ali; Azzam, Eman Zaki; Deghady, Akram; Abdellatif, Marzouk Arafa

doi:10.1016/j.endmts.2020.100049

Cited by 4 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The hallmark of HT is the high rate of positivity of thyroglobulin and thyroid peroxidase antibodies (anti‐TPO) 3 . Moreover, high anti‐TSH receptor antibody (TRAb) level is the mainstay in GD diagnosis 4 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Study of gut microbiome in Egyptian patients with autoimmune thyroid diseases

El‐Zawawy

Ahmed

El-Attar

et al. 2021

Int. J. Clin. Pract.

Self Cite

View full text Add to dashboard Cite

Autoimmune thyroid diseases (ATD) are the most common organspecific autoimmune diseases with complex pathogenesis including the interaction between environmental, genetic, and immunological factors. 1 ATD comprise two main entities; Hashimoto's thyroiditis (HT) and Graves' disease (GD) which are considered the most common forms of ATD. Although, GD and HT usually have opposing clinical manifestations; hyperthyroidism and hypothyroidism, respectively, however, in line with a more flexible view of ATD, HT and GD can cause both hyperthyroidism and hypothyroidism, even alternating between one form and the other. 2 The hallmark of HT is the high rate of positivity of thyroglobulin and thyroid peroxidase antibodies (anti-TPO). 3 Moreover, high anti-TSH receptor antibody (TRAb) level is the mainstay in GD diagnosis. 4 The human microbiome consist of 100 trillion bacteria, protozoa, fungi, and viruses. It is of paramount importance in

show abstract

Section: Introductionmentioning

confidence: 99%

“…3 Moreover, high anti-TSH receptor antibody (TRAb) level is the mainstay in GD diagnosis. 4 The human microbiome consist of 100 trillion bacteria, protozoa, fungi, and viruses. It is of paramount importance in…”

mentioning

confidence: 99%

Study of gut microbiome in Egyptian patients with autoimmune thyroid diseases

El‐Zawawy

Ahmed

El-Attar

et al. 2021

Int. J. Clin. Pract.

Self Cite

View full text Add to dashboard Cite

show abstract

“…These authors also noted that hyperthyroidism increased bone turnover and loss of bone mineral density. The applicant also argued that increased OPN plasma levels have been reported also for patients suffering from Graves' disease where increased T3 and T4 production is triggered by thyroid-stimulating immunoglobulins (El-Zawawy et al, 2020). According to the applicant's view, the available evidence would suggest that increased OPN plasma levels in patients suffering from hyperthyroidism is rather a consequence than a cause of the increased T3 and T4 levels.…”

Section: Resultsmentioning

confidence: 99%

“…In the response provided by the applicant, it is noted that evidence exists in the literature of increased hOPN plasma levels among patients with hyperthyroidism (increased T3 and T4 and decreased TSH) as well as of hOPN downregulation in hypothyroid patients (Alwakeel et al, 2012; Reza et al, 2013; Spaulding, 2013; El‐Zawawy et al, 2020). Reviewing the role and function of OPN in bone metabolism and noting this correlation between OPN and thyroid hormone plasma levels, these authors investigated whether plasma OPN could serve as a marker for thyroid function.…”

Section: Resultsmentioning

confidence: 99%

Safety of bovine milk osteopontin as a Novel food pursuant to Regulation (EU) 2015/2283

Turck¹,

Castenmiller²,

Henauw³

et al. 2022

EFS2

View full text Add to dashboard Cite

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on bovine milk osteopontin (bmOPN) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF concerns OPN derived from bovine whey. The NF is intended to be used at a maximum use level of 151 mg/L, in infant formula (IF), follow-on formula (FoF) and ready-to-eat dairy-based meals for children up to 35 months of age. As compared to the concentrations naturally present in cow's milk and concentrations found in IF on the market reported in the literature, the proposed use level of the NF represents an about 10-fold higher concentration of bmOPN. The intended use levels of the NF would provide bmOPN at a concentration within the range of human milk (hm) OPN. In a 6-month study, 14, 72 and 140 mg bmOPN/L in reconstituted (as consumed) IF were given to 279 infants in order to study possible effects on frequency and severity of adverse events, and growth, formula intake and stool consistency. Despite that a number of inconsistencies and limitations were noted in the study report, the Panel considers that the results obtained from this study do not raise safety concerns. Considering the source of the NF, that neither the toxicological studies nor the provided infant study do raise safety concerns, and the low bmOPN plasma levels in infants resulting from the consumption of the NF, the Panel considers that the margin of exposure (i.e. 36) between the NOAEL of the subchronic toxicity study (1,200 mg/ kg bw per day) and the highest P95 estimate for infants (33.4 mg/kg bw per day) is sufficient. The Panel concludes that the NF is safe under the proposed conditions of use.

show abstract

“…This can be explained by a cytokine storm which was reported to induce hyperthyroidism. 19 Moreover, both IFN-γ and IFN-α are known to be potent promoters of GD pathology; 20 meanwhile, different types of IFNs were found to be elevated in patients with COVID-19 cytokine storm. 21 Hence in GD & COVID-19 patients with cytokine storm, both GD and Graves' ophthalmopathy (GO) might be exaggerated.…”

Section: Hyperthyroidism Treatment In the Light Of Covid-19mentioning

confidence: 99%

Thyroid disease and covid‐19 infection: Case series

Allam

El‐Zawawy

Ahmed

et al. 2021

Clinical Case Reports

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel RNA coronavirus responsible for the coronavirus disease-19 (COVID-19) pandemic. The clinical manifestations of COVID-19 are variable, ranging from asymptomatic cases to severe respiratory affection, and were found to cause thyroid dysfunction in some cases. Our case series aim to shed the light on the effect of SARS-COV-2 infection on thyroid function, thyroid gland size, and treatment of thyroid dysfunction. We demonstrated three cases indicating that COVID-19 infection can accentuate thyrotoxic state and Graves' ophthalmopathy, aggravate hypothyroidism, increase thyroid gland volume, and in euthyroid individuals can induce some sort of thyroiditis, characterized by hyperthyroidism followed by hypothyroidism which is eventually followed by euthyroidism. Furthermore, treatment of thyroid disease was found to be affected by COVID-19 infection.The novel coronavirus (SARS-COV-2) was first discovered at the end of the year 2019 in Wuhan, China. After which, it rapidly spread, causing an epidemic throughout China, which then spread across the entire world, resulting in coronavirus pandemic. In February 2020, the World Health Organization (WHO) designated the disease COVID-19, which stands for coronavirus disease 2019. 1 SARS-CoV-2-specific antibodies and cell-mediated responses are induced following infection. Preliminary evidence suggests that some of these responses are protective, but this remains to be definitively verified. Moreover, it is unknown whether all infected patients develop a protective immune response and how long a protective effect might last. 2 Data about the effect of SARS-COV-2 on the thyroid function are scarce; however, one study addressed this effect and demonstrated that, out of 287 patients with confirmed SARS-COV-2, 58 patients had hyperthyroidism and 15 patients had hypothyroidism. 3 Our case series aim to shed the light on the effect of SARS-COV-2 infection on thyroid function, which will ultimately influence thyroid disease sequelae and management in patients with COVID-19.

show abstract

Osteopontin as a marker in thyroid disease: Relation to body mass index

Cited by 4 publications

References 17 publications

Study of gut microbiome in Egyptian patients with autoimmune thyroid diseases

Study of gut microbiome in Egyptian patients with autoimmune thyroid diseases

Safety of bovine milk osteopontin as a Novel food pursuant to Regulation (EU) 2015/2283

Thyroid disease and covid‐19 infection: Case series

Contact Info

Product

Resources

About